SCIENTIFIC PROGRAMME
SESSION I
BIOLOGY OF B-CELL
PRECURSOR ALL
SESSION II
BIOLOGY OF T-CELL ALL
SESSION III
MINIMAL RESIDUAL
DISEASE MONITORING
SESSION IV
INDIVIDUALIZED
MANAGEMENT OF ALL
SESSION V
NEW ADVANCES IN ALL
SESSION VI
CAR T-CELLS &
ALLOGENEIC HSCT
SESSION VII
FRONTLINE
INCORPORATION OF
BITES AND ADCS
SESSION VIII
T-CELL ALL AND
LYMPHOBLASTIC
LYMPHOMA
SESSION IX
PH AND PH-LIKE ALL
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
AS E-POSTERS
DISCLOSURES
the Bcl-2 inhibitor ABT-199 sensitized resistant PDX cells towards chemotherapy in vivo, thus
validating that inhibition of Bcl-2 could re-sensitize resistant cells to conventional
chemotherapy.
Conclusion:
In summary, we established a novel PDX in vivo model of acquired resistance to conventional
chemotherapy and identified different genomic alterations evolving in parallel in replicate
tumors. Nevertheless, identical downstream signaling mechanisms were affected in resistant
cells, indicating that different mechanisms of resistance might be overcome by the same
therapeutic rescue approach.